The presence of venous or arterial thrombosis, weight loss, abdominal pain, and a WHO (World Health Organization) performance status score ≥ 2, as well as the level of carbohydrate antigen 19-9 (CA 19-9) or carcinoembryonic antigen (CEA) and the maximal tumor size (with higher values in the locally advanced and metastatic groups), were significantly different between the groups (p < 0.001). The gene discussed is CEACAM5; the disease is neoplasm.